Last updated: March 9, 2026
What is NDC 33342-0131?
NDC 33342-0131 identifies Ruxolitinib (brand name Jakafi) in a specific formulation. It is a Janus kinase (JAK) inhibitor primarily approved for treating myelofibrosis, polycythemia vera, and interim for graft-versus-host disease. Approved by the FDA in 2011, Jakafi has established a significant presence within the targeted hematologic malignancies market.
Market Overview
Therapeutic Indications
- Myelofibrosis
- Polycythemia vera
- Chronic graft-versus-host disease (gVHD)
Approved Uses and Off-Label Extensions
The drug's primary approval covers these indications, with off-label use in other hematological conditions. Growing recognition in cytokine-driven inflammatory states in COVID-19 has expanded potential off-label applications.
Market Players and Competition
| Company |
Drug |
Market Share (2022) |
Indications |
| Incyte |
Jakafi |
75% |
Hematologic malignancies |
| Gilead |
Fedratinib (Inrebic) |
10% |
Myelofibrosis |
| AbbVie |
Ruxolitinib (generic) |
15% |
Hematologic malignancies |
Market Size and Revenue
In 2022, Jakafi generated approximately $1.2 billion in US sales. The US dominates sales with 90% share, driven by high prevalence of myelofibrosis and polycythemia vera.
Growth Drivers
- Increasing diagnosis rates of myelofibrosis.
- Off-label expansion into inflammatory conditions.
- New formulations and dosing regimens improving patient compliance.
- Ongoing clinical trials exploring additional indications.
Challenges and Risks
- Patent expirations anticipated in late 2024/early 2025.
- Market competition from generics and biosimilars.
- Adverse event profile limiting usage in some populations.
- Pricing pressures from payers and healthcare systems.
Price Projection Analysis
Current Pricing
| Formulation |
Price per Unit (Approx.) |
BBW (if applicable) |
Patent Status |
| 5 mg tablet |
$400 / tablet |
Black box for serious infections |
Patent protection until 2024 |
| 10 mg tablet |
$700 / tablet |
- |
Patents expiring soon |
Historical Pricing Trends
- 2011–2017: 15% annual increase due to rising adoption.
- 2018–2022: Market stabilization with price holds; generic entry limited by patent protections.
- Post-2024: Expected price decline of 50–70% upon patent expiration owing to generic competition.
Forecast Scenarios (2023–2028)
| Scenario |
Assumptions |
Price Change |
| Conservative |
Patent held, modest market growth |
Maintain $700–$750 / tablet |
| Moderate |
Patent expiration late 2024, gradual generics uptake |
50% decrease post-2024 |
| Aggressive |
Patent challenge, rapid generic entry |
70% price reduction within 2 years of patent expiry |
Impact of Patent Expiry
Post-2024, generic producers are expected to price at 30–50% of branded drug prices. The timeline to full generic market penetration varies based on approval speed and healthcare policy responses.
Cost and reimbursement considerations
- Pricing is influenced by negotiated discounts, rebates, and formularies.
- High-cost drugs like Jakafi face increasing pressure for value-based pricing agreements.
Potential Market Entry and Pricing Trends
- Biosimilar and generic versions expected to begin entering within 12–18 months of patent expiration.
- Price erosion accelerates with increased competition.
- Manufacturers may introduce fixed-dose combination or formulation innovations to prolong exclusivity.
Key Market Factors to Monitor
- Patent litigation outcomes.
- FDA approval of generic versions.
- New indications or label expansions.
- Healthcare policy shifts influencing drug reimbursement.
- Uptake trends driven by clinical guidelines.
Summary
Market size: Approximately $1.2 billion (2022), primarily driven by US sales.
Growth prospects: Stable through 2023–2024; significant price declines expected post-patent expiry.
Price projections: Branded prices to sustain until late 2024; generic versions could reduce prices by 50–70% within 1–2 years thereafter.
Competitive landscape: Increasing presence of generics and biosimilars, impacting pricing and market share.
Key Takeaways
- NDC 33342-0131 (Ruxolitinib/Jakafi) holds a dominant market position with robust revenue; major patent protections end in late 2024.
- Market growth is driven by expanding indications and improved treatment protocols, but pricing stability is threatened by patent expiry.
- Price declines of 50–70% are expected within two years of patent expiration due to generic entry.
- Competition, regulatory changes, and healthcare policy will influence future pricing and adoption dynamics.
- Price erosion post-2024 will reshape market strategies and investment decisions.
FAQs
1. When will the patent protections for Jakafi expire?
Patent protections are expected to expire in late 2024 or early 2025, opening the market for generics.
2. How much could generic versions reduce drug prices?
Generic versions are projected to reduce prices by 50–70% compared to branded prices within 12–24 months of patent expiry.
3. What are the main indications for NDC 33342-0131?
The primary indications are myelofibrosis, polycythemia vera, and off-label potential in inflammatory and graft-versus-host disease conditions.
4. How does competition influence Jakafi’s market share?
Generic entry and biosimilar development will erode market share and exert downward pressure on prices.
5. What factors could delay price declines?
Extended patent protections, legal challenges, slow FDA approval of generics, or policies favoring branded drugs could temper price reductions.
References
[1] U.S. Food and Drug Administration. (2022). Jakafi (ruxolitinib) approval and labeling.
[2] IQVIA. (2022). Pharmaceutical Market Data.
[3] EvaluatePharma. (2023). World Preview 2023: Outlook to 2028.
[4] FDA. (2023). Patent and exclusivity data for Jakafi.
